Caution with the use of lopinavir/ritonavir in severely ill patients for the treatment of sars-cov-2: a report of severe jaundice - Université de Lille Accéder directement au contenu
Article Dans Une Revue The American Journal of Gastroenterology Année : 2020

Caution with the use of lopinavir/ritonavir in severely ill patients for the treatment of sars-cov-2: a report of severe jaundice

Résumé

We investigated the potential hepatotoxicity of lopinavir/ritonavir recently used in the treatment of Severe Acute Respiratory Syndrome Coronavirus. This is a retrospective cohort of critical patients in a teaching hospital: 12 treated with lopinavir/ritonavir and 30 in the standard-of-care group. Elevation occurred more frequently in patients treated with lopinavir/ritonavir (33% vs 6.7%). Caution is advised regarding the use of lopinavir/ritonavir in the most severe cases of Severe Acute Respiratory Syndrome Coronavirus.

Dates et versions

hal-04466033 , version 1 (19-02-2024)

Identifiants

Citer

Clementine Levy, Guillaume Lassailly, Erika Parmentier, Thibault Duburcq, Philippe Mathurin, et al.. Caution with the use of lopinavir/ritonavir in severely ill patients for the treatment of sars-cov-2: a report of severe jaundice. The American Journal of Gastroenterology, 2020, The American Journal of Gastroenterology, 115, pp.1716-1718. ⟨10.14309/ajg.0000000000000828⟩. ⟨hal-04466033⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More